ClinicalTrials.gg
CompletedNCT07793370Updated Oct 30, 2026

Evaluation of PTHrP, RANKL, and OPG Levels in Periodontal Health and Diseases

An observational study in Periodontitis, Gingivitis and Periodontal Disease, sponsored by Abant Izzet Baysal University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Abant Izzet Baysal University · Observational

Updated Oct 30, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
81
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Periodontitis by Abant Izzet Baysal University — 2 open to participants now, 2 under way, none of them phase 3. Periodontitis · Abant Izzet Baysal University.

Started
2026
with 2 others
Observational
7 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Periodontitis by Abant Izzet Baysal University, this one is one of 3 that started in 2026, is one of 7 observational ones, and was the 10th registered.

Periodontitis

1,235 studies on the registry are indexed under Periodontitis; 298 are open to participants now.

Browse Periodontitis studies →

Open to participants now

2 of the 11 studies in Periodontitis by Abant Izzet Baysal University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 160 Periodontitis studies recruiting now, 79 (49%) set no upper age limit and 60 (38%) stop at 75 or younger; 12 take children under 18; 77 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Periodontitis by Abant Izzet Baysal University, or all of them as a file.
02

Study summary

This observational study aims to evaluate the levels of specific biological markers-Parathyroid Hormone-Related Protein (PTHrP), RANKL, and Osteoprotegerin (OPG)-in the gingival crevicular fluid of individuals with different gum health conditions. The study includes a total of 81 participants, divided equally into three groups: 27 with healthy gums, 27 with gingivitis, and 27 with periodontitis. During a routine dental visit, participants undergo a standard periodontal examination to measure clinical signs such as plaque levels, gum bleeding, and pocket depths. Additionally, small sterile paper strips are gently placed in the gum crevices for 30 seconds to collect fluid samples. These fluid samples are then analyzed in a laboratory to understand how these specific proteins relate to gum health and the severity of gum disease.

Read the detailed description

Periodontitis is a chronic inflammatory disease characterized by the destruction of tooth-supporting tissues and alveolar bone loss, primarily driven by an imbalance in bone metabolism. The regulation of bone turnover relies heavily on the balance between RANKL, which promotes osteoclast activation, and OPG, its natural inhibitor. Furthermore, PTHrP acts as a critical autocrine and paracrine regulator in periodontal tissue health and alveolar bone repair. The primary rationale of this research is to investigate the dynamic role of PTHrP in periodontal pathogenesis during both the inflammatory and tissue-destruction phases, evaluating its potential as a biological marker. Following a comprehensive clinical periodontal examination by a single calibrated clinician, specific sampling sites are isolated with cotton rolls and gently air-dried. Supragingival plaque is carefully removed prior to sampling. Gingival crevicular fluid (GCF) is then collected from these designated interproximal sites using sterile filter paper strips, which are inserted into the sulcus until mild resistance is felt and left in place for 30 seconds. Samples contaminated with blood or saliva are immediately excluded. The exact volume of the collected fluid is quantified using an electronic volume meter (Periotron 8010). All valid strips are subsequently transferred to microcentrifuge tubes and preserved at -80°C until laboratory processing. The biochemical quantification of PTHrP, RANKL, and OPG levels is performed via commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits in accordance with the manufacturer's protocols.

03

Conditions studied

  • Periodontitis
  • Gingivitis
  • Periodontal Disease

Keywords

  • Parathyroid Hormone-Related Protein
  • RANK Ligand
  • Osteoprotegerin
  • Gingival Crevicular Fluid
  • Biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of adult individuals seeking dental care at the Department of Periodontology, Faculty of Dentistry, Bolu Abant Izzet Baysal University. The population includes a total of 81 participants representing three distinct periodontal conditions: individuals with a healthy periodontium, individuals diagnosed with gingivitis, and individuals diagnosed with Stage III periodontitis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 18 years and older.
  • Presence of at least 20 natural teeth, excluding third molars.
  • For the Periodontally Healthy GrouP: PD ≤ 3 mm, BOP \< 10%, and no interproximal CAL or RBL.
  • For the Gingivitis Group: PD ≤ 3 mm, BOP ≥ 30%, and no interproximal CAL or RBL.
  • For the Periodontitis Group: Diagnosed with Stage III periodontitis (interproximal CAL ≥ 5 mm, PD ≥ 6 mm, and RBL extending to the middle third of the root or more apically).

Exclusion criteria

Exclusion Criteria:

  • Presence of systemic diseases that may affect periodontal tissues (e.g., cardiovascular diseases, atherosclerosis, immune system diseases, rheumatoid arthritis, obesity, cancer, and diabetes).
  • Use of antibiotics within the last 3 months.
  • Use of any medication that may affect periodontal tissues.
  • Presence of infectious diseases such as , , or tuberculosis.
  • Pregnancy or lactation.
  • History of periodontal treatment within the last 6 months.
  • Smoking
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
81 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Periodontally Healthy

    27 individuals with probing depth (PD) ≤ 3 mm, bleeding on probing (BOP) \< 10%, and no interproximal clinical attachment loss (CAL) or radiographic bone loss (RBL).

    Other: Routine periodontal clinical examination and GCF collection

  • Gingivitis

    27 individuals with PD ≤ 3 mm, BOP ≥ 30%, and no CAL or RBL.

    Other: Routine periodontal clinical examination and GCF collection

  • Periodontitis

    27 individuals diagnosed with Stage III periodontitis, characterized by interproximal CAL ≥ 5 mm, PD ≥ 6 mm, and RBL extending to the middle third of the root or more apically.

    Other: Routine periodontal clinical examination and GCF collection

Interventions

  • OtherRoutine periodontal clinical examination and GCF collection

    A comprehensive clinical periodontal examination is performed by a single calibrated examiner using a periodontal probe. The examination includes the measurement of Plaque Index (PI), Gingival Index (GI), PD, and CAL. For GCF collection, the specified interproximal sites are isolated with cotton rolls, gently air-dried, and cleared of supragingival plaque. GCF samples are then collected using sterile filter paper strips inserted into the sulcus until mild resistance is felt and left in place for 30 seconds.

06

What researchers measure

Primary outcomes

  1. GCF Level of PTHrP

    The concentration of PTHrP in GCF samples will be quantitatively measured using commercial ELISA kits.

    Time frame: Baseline (Single time point during the clinical examination)

  2. GCF Level of RANKL

    The concentration of RANKL in GCF samples will be quantitatively measured using commercial ELISA kits.

    Time frame: Baseline (Single time point during the clinical examination)

  3. GCF Level of Osteoprotegerin

    The concentration of OPG in GCF samples will be quantitatively measured using commercial ELISA kits.

    Time frame: Baseline (Single time point during the clinical examination)

Secondary outcomes

  1. Probing Depth (PD)

    PD will be measured using a periodontal probe at six sites per tooth (mesiobuccal, midbuccal, distobuccal, mesiopalatal/lingual, midpalatal/lingual, and distopalatal/lingual). Measurements will be rounded to the nearest millimeter.

    Time frame: Baseline (Single time point during the clinical examination)

  2. Clinical Attachment Level (CAL)

    CAL will be calculated by measuring the distance from the cementoenamel junction to the base of the probable pocket using a periodontal probe.

    Time frame: Baseline (Single time point during the clinical examination)

  3. Gingival Index (GI)

    GI will be evaluated according to the method described by Löe and Silness. Four surfaces of each tooth (buccal, lingual/palatal, mesial, and distal) will be scored to calculate the full-mouth average GI score.

    Time frame: Baseline (Single time point during the clinical examination)

  4. Plaque Index (PI)

    PI will be evaluated according to the method described by Löe and Silness. Four surfaces of each tooth will be scored to calculate the full-mouth average PI score.

    Time frame: Baseline (Single time point during the clinical examination)

07

Study locations

1 site
  • Bolu Abant İzzet Baysal University, Faculty of Dentistry, Department of Periodontology
    Bolu, Gölköy 14030, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Jul 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Aug 28, 2026
StartActual
Jun 1, 2026
Primary completionActual
Jul 24, 2026
CompletionActual
Aug 20, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Study completion
Aug 31, 2026→Aug 20, 2026 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Study completion Aug 31, 2026→Aug 20, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07793370
Responsible party
Bilge MERACI YILDIRAN (Assistant Professor, Abant Izzet Baysal University) — Principal investigator
First posted
Aug 28, 2026
Start date
Jun 1, 2026
Primary completion
Jul 24, 2026
Completion
Aug 20, 2026
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion